Contact Us
Drug Search Results
More Filters [+]

CN-201

Alternative Names: cn-201, cn 201, cn201
Latest Update: 2025-01-09
Latest Update Note: News Article

Product Description

CN-201 is being developed by Curon Biopharmaceutical (Shanghai) Co.,Ltd for the treatment of Acute Lymphoblastic Leukemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05579132?term=CN-201&draw=2&rank=1)

Mechanisms of Action: CD19 Inhibitor,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CN-201

Countries in Clinic: China

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CN201-101

P1

Recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2025-06-01

CN201-103

P2

Recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2025-05-31

CTR20210029

P1

Not yet recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

None

Recent News Events

Date

Type

Title

01/09/2025

News Article

 Where is the next Chinese drug that will make MNCs compete to grab orders?

10/31/2024

News Article

 Merck Announces Third-Quarter 2024 Financial Results

10/01/2024

News Article

 Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical

08/09/2024

News Article

 Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions